Kintor Announces Presentation of Preclinical Data at AACR 2021
Release time：2021-04-09 17:01
Suzhou, Apr.9, 2021--真人直营投注网站 (stock code 9939.HK, “Kintor Pharmaceutical” or the “Company”), a clinical-stage biotechnology company developing small molecule and biological therapeutics, today announced two poster presentations of preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021, including proxalutamide(GT0918) to treat COVID-19 and a c-Myc inhibitor to treat blood cancer.
In light of the COVID-19 pandemic, this year’s AACR annual meeting will be held in a virtual format over two weeks, April 10-15 and May 17-21.
■ E-Poster
Title: Repurposing 2nd generation androgen receptor antagonist Proxalutamide to treat COVID-19
Abstract Number: 711
Link: https://www.abstractsonline.com/pp8/#!/9325/presentation/1754
Title: Discovery of GT19077, a c-Myc/Max Protein-Protein Interaction(PPI) Small Molecule Inhibitor, and GT19506, a c-Myc protein degrader, for Targeting c-Myc-Driven Blood Cancers
Abstract Number:1265
Link: https://www.abstractsonline.com/pp8/#!/9325/presentation/2350
The AACR e-poster website will be launched on Saturday, April 10, the first day of the virtual AACR Annual Meeting. All e-posters will be made available for browsing on this date.
recommend News
2024-07-01
2024-06-05
Find Us
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn